nAChRα9α10 Discovery Program (Rapport Therapeutics)

N/A

Report date: 2024/09/25 09:54:28
NME

Base Information

Drug NamenAChRα9α10 Discovery Program (Rapport Therapeutics)
Drug Alias Namealpha-9alpha-10 nicotinic acetylcholine receptor modulators (Rapport Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNicotinic acetylcholine receptor alpha9/alpha10 modulators
TargetsNicotinic acetylcholine receptor alpha9/alpha10
Therapy Area/IndicationsHearing Loss
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRapport Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRapport Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHearing Loss
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A